Status:

TERMINATED

Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT)

Lead Sponsor:

Leiden University Medical Center

Conditions:

Giant Cell Tumor of Bone

Osteoclastoma

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

This is a multicenter, randomised phase II trial in patients with high risk GCT. Primary objective: * Determine if adjuvant zoledronic acid improves the 2 years recurrence rate of 'high risk' GCT as...

Detailed Description

GCT is a potentially malignant tumour that presents with a locally destructive osteolytic lesion. The high risk GCT are characterized by a high recurrence rate around the 40-45%. Zoledronic acid is a ...

Eligibility Criteria

Inclusion

  • Signed written informed consent
  • Male or female \> 18 years of age
  • Histologically proven GCT treated with surgery
  • High risk GCT defined as minimal one or more of the following:
  • Recurrent GCT
  • GCT located in the pelvis, sacrum, spine, distal ulna or growth in soft tissue
  • GCT grade III
  • Pathological fracture in GCT
  • Absence of local adjuvant therapy (cryosurgery or phenol instillation)
  • Neutrophils \> 1.5x109/L, platelets \> 100x109/L, and Hb \> 6 mmol/l
  • Bilirubin level \< 1.5 x ULN
  • ASAT and ALAT \< 2.5 x ULN
  • Adequate renal function as defined by: serum creatinine clearance \> 60 cc/min
  • Expected adequacy of follow-up

Exclusion

  • Unresectable or metastatic GCT and grade IV GCT
  • Prior bisphosphonate usage, except preoperative treatment with zoledronic acid up to 3 months before surgery
  • Other previous malignancy within 5 years, with exception of a history of a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix
  • Known hypersensitivity reaction to any of the components of the treatment
  • Pregnancy or lactating
  • Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent

Key Trial Info

Start Date :

December 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2015

Estimated Enrollment :

15 Patients enrolled

Trial Details

Trial ID

NCT00889590

Start Date

December 1 2008

End Date

July 1 2015

Last Update

January 26 2016

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

University hospital Gent

Ghent, Belgium, 9000

2

Academic Medical Center, University of Amsterdam

Amsterdam, Netherlands, 1100DD

3

Groningen University Medical Center

Groningen, Netherlands, 9700 RB

4

Leiden University Medical Center

Leiden, Netherlands, 2300RC